Search the Newsreel

Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market

Viking Therapeutics, Inc. (VKTX) stock underperformed the broader market, falling 5.15% in the latest session compared to losses for the S&P 500, Dow, and Nasdaq. The company also underperformed the Medical sector over the past month. Investors are anticipating its upcoming earnings release on …

Viking Therapeutics (VKTX) Appoints Dorothy Gemmell To Board As Commercial Focus Grows

Viking Therapeutics (VKTX) has appointed Dorothy Gemmell, a healthcare executive with expertise in commercial execution and digital health, to its Board of Directors. This appointment signals a growing commercial focus for the clinical-stage biopharmaceutical company as it advances its pipeline in obesity and metabolic …

Dorothy Gemmell Joins Viking Board After 25+ Years in Healthcare

Viking Therapeutics (NASDAQ: VKTX) has appointed Dorothy Gemmell to its Board of Directors, leveraging her over 25 years of experience in healthcare, digital health, and commercialization. Her expertise is expected to be crucial as Viking advances its metabolic pipeline, particularly in preparation for the …

Press Release: Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors

Viking Therapeutics has announced the appointment of Dorothy Gemmell to its Board of Directors, effective immediately. Gemmell brings extensive experience in commercialization leadership within the biotechnology industry, having held senior roles at companies like Genentech, Amgen, and Onyx Pharmaceuticals. Her expertise is expected to …

Viking Therapeutics’ Q2 results arrive after markets close

Viking Therapeutics (NASDAQ: VKTX) is scheduled to release its second-quarter 2026 financial results after market close on Wednesday, July 29, 2026. The company will also host a conference call on the same day at 4:30 p.m. Eastern Time to discuss the results and provide …

Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm

Kuehn Law, PLLC is investigating whether officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX) breached their fiduciary duties to shareholders through potential self-dealing. The firm is encouraging long-term VKTX stockholders to contact them for a free and no-obligation consultation to discuss potential damages …

Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026

Viking Therapeutics, Inc. announced it will release its financial results for the second quarter of 2026 after market close on Wednesday, July 29, 2026. The company will also host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the …

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1

Key Points Viking Therapeutics just launched its next-gen weight loss program. Novo Nordisk and Eli Lilly are already deep into the development process with comparable programs. Viking's candidate is thus going to need to produce some stellar data to be competitive. 10 stocks we …

Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes."

Key Points The key trial results for VK2735 are still years away. There are some useful indicative results coming from a phase 1 maintenance trial over the next six or so months. VK2735 demonstrated the potential to generate relatively swift weight loss in phase …

Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note

Viking Therapeutics (VKTX) stock performed strongly, gaining 1.95% while the broader market indices like the S&P 500, Dow, and Nasdaq fell. The company's stock has risen 19.72% over the past month, outperforming its sector and the S&P 500. Analysts expect Viking Therapeutics to report …

Viking Therapeutics (VKTX) Could Be 61% Undervalued As It Starts VK3019 Trial

Viking Therapeutics (VKTX) has initiated a Phase 1 study for VK3019, a potential weight loss therapy. Despite recent stock fluctuations, the company shows strong long-term momentum, with Simply Wall St's analysis suggesting it is 61% undervalued compared to a fair value of $92.72. However, …

Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?

Viking Therapeutics (VKTX) is set to report its second-quarter 2026 earnings, with investors keenly focused on updates regarding its pipeline, particularly the obesity drug VK2735. The company's earnings have consistently missed estimates, and with no marketed drugs, revenue generation is not anticipated. Key areas …

Law firm probes Viking Therapeutics officers for possible self-dealing harming shareholders

Kuehn Law, PLLC is investigating whether officers and directors of Viking Therapeutics, Inc. breached their fiduciary duties through potential self-dealing, which could result in shareholder damages. The firm is encouraging long-term shareholders to contact them for free consultations to protect their rights.

Viking Therapeutics (VKTX) Stock Looks Stretched After a 6x Five Year Run

Why Viking Therapeutics (VKTX) Is Up 8.0% After Advancing New Obesity Drug VK3019 Into Phase 1 – And What's Next

Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know

Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know

Why Is Viking Therapeutics (VKTX) Up 3.2% Since Last Earnings Report?

Earnings call transcript: Viking Therapeutics Q1 2026 sees widened net loss

VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot

Viking Therapeutics Gears Up for Q1 Earnings: Here's What to Expect

Assessing Viking Therapeutics (VKTX) Valuation As Obesity Trial Optimism Meets Richer Balance Sheet Ratios

VKTX Shares Garner Retail Attention Ahead Of Q4 Earnings Report

Viking Therapeutics Stock Forecast 2026–2030 | Future Outlook

Viking Therapeutics to Report Q4 Earnings: Here's What to Know